Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Jad M Abdelsattar, M.D, FACS

Breast Surgical Onc · University of Oxford

View

Dr. Lauren Kopicky

Breast Surgical Onc · Cleveland Clinic

View

Dr. Jennifer Plichta

Breast Surgical Onc · Duke University

View

Dr. Sarah Blair

Breast Surgical Onc · UCSD

View

Dr. Karen Goodwin

Breast Surgical Onc · UCSF

View

Dr. Christin Collins

Breast Surgical Onc · MetroHealth

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Todd Rosengart

Cardiac Surgery · BCM

View

Dr. Larry Kaiser

Thoracic Surgery · UPenn

View

Dr. Neri Cohen

Thoracic Surgery · XVIVO

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    External Validation of a Pragmatic Scoring System for Predicting Upgrade of Atypical Ductal Hyperplasia at the Time of Surgery.

    Dec 23, 2025DOI: 10.1245/s10434-025-18803-7Journal ArticleASO

    Written by: Walter R F DonicaDimond S ShartzerVarun G RamakrishnanElsa KuhlDaniel D MaisKelly M McMastersNicolas Ajkay

    Find these authors on Roon

    NA
    Dr. Nicolas Ajkay
    Breast Surgical Onc · University of Louisville

    Summary

    BACKGROUND: Atypical ductal hyperplasia (ADH) carries a variable risk of upgrade at the time of surgery to ductal carcinoma in situ (DCIS) or invasive malignancy. We sought to externally validate a pragmatic upgrade risk scoring system previously demonstrated to have an upgrade rate of 0-2% in patients with a risk score of 0 out of 5.METHODS: A multicenter, retrospective review of all percutaneous biopsies containing ADH was performed from 2017 to 2023. Women aged ≥ 18 years who underwent diagnostic mammography and surgical excision for pathologic correlation were included.RESULTS: Among the 183 cases included, the mean age was 58 years ± standard deviation 11, and 91 patients (50%) reported a family history of breast cancer. Most biopsies were stereotactic (75%), vacuum-assisted (84%), and used 9-gauge needles (73%). Three of 14 (21%) patients with a risk score of 0 were upgraded to DCIS following surgical excision. Seven (19%) patients had a risk score of 1 upgraded - six to DCIS and one to an estrogen receptor-positive/progesterone receptor-positive/human epidermal growth factor receptor 2-negative invasive ductal carcinoma measuring 5.45 mm in largest diameter. On multivariate analysis, age, mammographic lesion size, and suspicion of DCIS on biopsy were predictive of upgrade.CONCLUSIONS: The risk model evaluated generally predicts the risk of upgrade of ADH at excisional biopsy but may underestimate the upgrade rate in the lowest-risk cohort. Because of the small sample size, further work is needed to determine whether the rate of upgrade is truly low enough in this lowest-risk cohort to recommend against excisional biopsy.
    NADr. Nicolas Ajkay

    Dr. Nicolas Ajkay

    Surgery · Breast Surgical Oncology
    University of Louisville
    nicolasa